Detalhe da pesquisa
1.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
N Engl J Med
; 389(10): 877-888, 2023 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351564
2.
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med
; 387(3): 205-216, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658024
3.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med
; 384(11): 989-1002, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33567185
4.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA
; 331(1): 38-48, 2024 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38078870
5.
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.
Diabetes Obes Metab
; 25(11): 3171-3180, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37424165
6.
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison.
Diabetes Obes Metab
; 25(9): 2626-2633, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344384
7.
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Diabetes Obes Metab
; 24(1): 94-105, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514682
8.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Diabetes Obes Metab
; 24(8): 1553-1564, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35441470
9.
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
N Engl J Med
; 389(24): 2304-2305, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38091543
10.
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data.
Int J Obes (Lond)
; 45(5): 923-933, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462358
11.
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
Int J Obes (Lond)
; 45(8): 1687-1695, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083744
12.
Effect of a functional fibre supplement on glycemic control when added to a year-long medically supervised weight management program in adults with type 2 diabetes.
Eur J Nutr
; 60(3): 1237-1251, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32642971
13.
The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016.
Crit Rev Food Sci Nutr
; 60(10): 1614-1630, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-30896252
14.
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Lancet
; 392(10148): 637-649, 2018 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30122305
15.
Ligne directrice C-CHANGE pour l'harmonisation des lignes directrices nationales de prévention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada: mise à jour 2022.
CMAJ
; 195(1): E21-E42, 2023 01 09.
Artigo
em Francês
| MEDLINE | ID: mdl-36623864
16.
Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update.
CMAJ
; 194(43): E1460-E1480, 2022 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36343954
17.
L'obésité chez l'adulte : ligne directrice de pratique clinique.
CMAJ
; 192(49): E1757-E1775, 2020 Dec 07.
Artigo
em Francês
| MEDLINE | ID: mdl-33288515
18.
Obesity in adults: a clinical practice guideline.
CMAJ
; 192(31): E875-E891, 2020 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32753461
19.
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.
CMAJ
; 190(40): E1192-E1206, 2018 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30301743
20.
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
Obesity (Silver Spring)
; 31(3): 703-715, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36655300